Price Change Optimization and Key Trends Impacting Generic GTNs
|
|
- Derick Fowler
- 6 years ago
- Views:
Transcription
1 Price Change Optimization and Key Trends Impacting Generic GTNs Jeff Baab, Vice President, Life Sciences Jennifer Sharpe, Senior Director, Revenue Analytics Collaborative March 2016 Bringing data to life. March 2016 Proprietary Information
2 Agenda Introductions Poll the Audience Price Change Optimization Industry Insights Trends Impacting Generic Price Change Management & GTNs Federal Budget Generic Inflation Penalty ACA Final Rule: Generics Watch List Q&A March 2016 Proprietary Information 2
3 Price Change Optimization Price Change Optimization Industry Insights March 2016 Proprietary Information
4 Utilization Path Drives GTN Rate Some fees are owed on all sales: Distribution service fees Prompt pay Data fees Fees owed: 3 rd party contract fees Billback to contracted entity Billback Sale at Retail Contract Price Sale at PHS Contract Price Manufacturer Drug WAC Wholesaler CB Issued Sale at Whlsr Contract Price Sale at FSS Contract Price CB Requested Per Contract Price Fees owed: Program admin fees Marketing fees Non contract sales fee Per Unit Rebates Price protection Shelf stock allowances Fees owed: IFF May not owe whlsr fees on Gov t Sales Retailer w/ Manufacturer Contract 340b CE Buying Off of PHS Contract Gov t Entity Buying Off of FSS Retailer w/out Manufacturer Contract May have multiple contract prices. Net Price #1 Net Price #2 Net Price #3 Net Price #4 March 2016 Proprietary Information 4
5 Payment Methods Are Complicated & Require Different Data Sets There are adjudication and forecasting challenges related to generic fees and rebates because the payment formulas are complicated and require multiple data sets. Here are some examples: Fee or Rebate Type Example of Calculation Methodology Data Sets Required Challenges Distribution Service Fee Apply fee % against direct sales to customer Direct Sales Direct Sales may not be readily available in Contracting System Shelf Stock Adjustments (New WAC Old WAC) x Average Inventory Level over Specified Period Wholesaler Inventory Data Validating reasonableness of inventory data Product Rebates and/or Service Fees Apply % against subset of customer s Net Sales Direct sales, adjustments, returns, chargebacks Anticipating utilization; tying together data sets and calculating net sales Per Unit Rebates Rebate % Applied to Sales from Wholesaler to Specific End Customer Chargeback data Need to identify sales to specific customer w/in a contract March 2016 Proprietary Information 5
6 Tracking Impact of Price Changes on Line Items Notes Arrows indicate impact of contract price change on line item (not considering changes to utilization) GTN lines that stay flat grow as % of net sales when contract price Utilization shifts can have dramatic impact on net sales & GTN rates Price basis for some GTN line items can vary by wholesaler Fee or Rebate Type Contract Price Contract Price Prompt Pay Distribution Service Fees Redistribution Fees Data Fees Program Admin Fee Marketing Fees Floor Stock Adjustments Price Protection Per Unit Rebates Chargebacks Billbacks Medicaid Returns March 2016 Proprietary Information 6
7 Price Change Optimization Benchmarking & Better Practices Understand Price Change Impact Successful Practices: Finance/Accounting assist Trade/Pricing to calculate price change impact Pitfalls: accrual or forecasting miss, significant negative impact on product profitability Cross-functional Communication Successful Practices: Pricing Committee and/or Price Change Mgt Protocol inclusive of Government Pricing, Finance and Accounting review/approval Pitfalls: surprise true-ups, significantly under accrued March 2016 Proprietary Information 7
8 Price Change Optimization Benchmarking & Better Practices Process Documentation Successful Practices: SOPs, WIs, process flows Pitfalls: Lynch Pin, human error, lost documentation Investment in Systems Successful Practices: Automated solution integrated with a Gross-to-Net accrual management application Understand price change and/or rebate impact to adjudication system Pitfalls: manual, paper process driven by s and Excel. March 2016 Proprietary Information 8
9 Price Change Optimization Trends Impacting Generic Price Change Management & GTNs March 2016 Proprietary Information
10 Manufacturer M&A Activity Why? Branded companies have acquired generic companies as entry point to generic business and vice versa. Diversification, path to AG launches, reduction of risk Acquisitions can remove competitors from marketplace. Challenges: Brands and generics look at GTNs differently Completely different business models and contracting Speed and volumes of the generic world Recent deals involving generic manufacturers: Lannett Company acquired Kremers Urban Pharma ($1.2 B) Teva agreed to acquire Allergan s generic portfolio ($40.5 B) Hikma Pharma acquired Roxane Labs (~$2 B) Endo International acquired Par Pharmaceuticals ($8 B) Mylan lost bid to acquire Perrigo ($34 B) March 2016 Proprietary Information 10
11 Supply Chain Consolidation WBAD (Walgreens - ABC) McKesson Rite Aid Red Oak (CVS-Cardinal) Walgreens Rite Aid (pending) CVS - Omnicare CVS - Target Analysis of a Deal: CVS Target CVS bought Target s pharmacy business for $1.9B Target pharmacies will be rebranded and operate as CVS within Target stores Target s >80 retail clinics will rebrand as CVS MinuteClinics Target primarily bought generics directly and branded products from McKesson. Branded utilization will shift to Cardinal and generics to Red Oak, who supplies CVS. May shift flow of specialty products from Diplomat (supplied Target) to CVS Health s Specialty Connect program. March 2016 Proprietary Information 11
12 Generic Price Inflation is Slowing Down From , saw phenomena where generic prices were actually increasing for majority of products on the market. Due to various reasons such as raw material or product shortages and competitors dropping out of the market. Recently, the FDA has made a concerted effort to clear its backlog of ANDA applications which is changing the trajectory of generic competition and pricing. Wholesaler earnings reports, where margins are hurting, are clear indications that generic prices are starting to fall again. March 2016 Proprietary Information 12
13 Introduction of Biosimilars in Marketplace Affordable Care Act paved way for FDA to approve biosimilars, which are essentially a generic of a biologic. The approval pathways and costly manufacturing processes increase cost of bringing a biosimilar to the market. The price erosion for the branded biological drugs is not expected to be as great as for traditional generic drugs. While the market is still shaping, prices for biosimilar products may be 65% -85% of their originators. Biosimilars have huge potential in the U.S. market since there is an upcoming patent cliff on several blockbuster biologic products. Success of a given biosimilar will depend on many factors, including price, duration of therapy, experience of physicians with the products and patient preference. March 2016 Proprietary Information 13
14 Price Change Optimization Federal Budget Generic Inflation Penalty March 2016 Proprietary Information
15 Quick Background on Inflation Penalty Concept Inflation Penalty Amounts to a price protection penalty that is added to the rebate per unit paid on Medicaid utilization. Historically Inflation penalty has always been applicable to single source and innovator multi-source drugs March 2016 Proprietary Information 15
16 Branded Medicaid URA & Inflation Penalty Primer Greater of (AMP * 23.1%) or (AMP - BP) Current AMP Baseline AMP x CPI-U New CPI-U Baseline Unit Rebate Amount (URA) = (Basic Rebate + Additional Rebate) What is CPI-U? An economic indicator published by the Bureau of Labor Statistics that represents the prices paid by urban consumers for a representative basket of goods and services. It is represented by a number, such as , , etc. that can be compared over time to measure inflation. What does this mean? If AMP grows faster than inflation between the launch quarter and current quarter, that additional growth is added to URA as an inflation penalty. March 2016 Proprietary Information 16
17 Generic Inflation Penalty: What We Know What Changed The budget deal signed by President Obama on Oct 26th, 2015 requires manufacturers that participate in MDRP pay an inflation penalty on non-innovator drugs ( N drugs). This penalty has only applied to S and I drugs historically. Effective Date The additional rebate is expected to become effective in 1Q March 2016 Proprietary Information 17
18 Generic Inflation Penalty: Where Do We Stand? First Marketed Before April 1, 2013 First Marketed After April 1, 2013 Baseline AMP 3Q 2014 Fifth full calendar quarter after which the drug is marketed as an N drug Baseline CPI-U The CPI-U for Sept 2014 The CPI-U for the last month in the baseline AMP quarter March 2016 Proprietary Information 18
19 New URA Calculation for N Drugs AMP x 13% Current AMP Baseline AMP x CPI-U New CPI-U Baseline Basic Rebate + = Total URA Additional Rebate Note: The Current CPI-U is the CPI-U value of the month prior to the quarter being calculated. March 2016 Proprietary Information 19
20 Price Change Optimization ACA Final Rule: Generics Watch List March 2016 Proprietary Information
21 Final Rule: Why Does It Matter? Final Rule sets forth new and revised regulations that affect AMP and BP reporting, Medicaid rebate processing, and reimbursement rates related to Medicaid utilization. Many provisions of the rule have an effective date of April 1, Certain provisions will be effective as of April 1, The Final Rule may impact a manufacturer s brand strategies, financial liabilities, and compliance and contracting policies, processes, and systems. March 2016 Proprietary Information 21
22 General Provisions that May Affect Generic AMPs Area of Impact Inclusion of U.S. Territories in Definition of States Class of Trade - Specialty Pharmacies / Home Health / Infusion Prompt Pay Offered to RCPs Description of Guidance Effective April 1st, 2017, manufacturers may have to pay Medicaid rebates on Medicaid utilization in five U.S. territories, including Puerto Rico. Additionally, transactions to customers in the territories will be eligible for AMP and BP reporting. These types of customers are eligible for AMP if they also meet the definition of RCPs. Only exclude CPPD offered to wholesalers. CPPD offered to AMP eligible customers, like RCPs, should be included in AMP as a price concession. March 2016 Proprietary Information 22
23 Clarifications Related to Authorized Generics Area of Impact Treatment in AMP of Sales to Secondary Manufacturer Treatment in AMP when Manufacturer Owns Both Brand and AG Description of Guidance Include sales of an AG to the secondary manufacturer in the AMP of the brand only when secondary manufacturer acts as wholesaler selling to RCPs. Final Rule specifically excludes sales to a secondary manufacturer that relabels the product. When a single manufacturer markets both the original and AG under a common NDA, the AMP and Best Price calculations are to be blended across the NDC-9s. Subsequent Q&A during the CMS webinar indicated that CMS expects separate AMPs to be filed for the brand and AG in this scenario. March 2016 Proprietary Information 23
24 Definition of Covered Outpatient Drugs Area of Impact Definition of Multi-Source Drugs Description of Guidance CMS is now defining original NDA to mean an NDA under section 505(b) of the Food, Drug and Cosmetic Act (FDCA), as opposed to an ANDA under section 505(j) of the FDCA. This may result in drugs that have been marketed as generic drugs, for all intents and purposes, being treated as branded drugs in the Medicaid Program. CMS has created a narrow exception through which manufacturers may request their drugs continue to be treated as N drugs. Subsequent operational guidance on this matter is anticipated from CMS. March 2016 Proprietary Information 24
25 Move Towards AAC as Basis for Pharmacy Reimbursement States are also being asked to shift to AAC (NADAC, etc.) based reimbursement models rather than EAC (AWP). Also, FULs will be calculated at 175% of weighted average mamps but the greater of FUL or NADAC will set FUL. Potential Impact Generally, ACA FULs < State MACs < Pre- ACA FULs ACA FULs will likely act as new, lower ceiling for some product classes Considerations & Challenges Complicated to sort out impact of FULs and MACs RCP reimbursement likely to go down Need to manage relationships and pricing w/ RCPs Questions from Final Rule Spillover impact to pharmacy reimbursement from commercial plans? How will RCPs react to lower reimbursement? March 2016 Proprietary Information 25
26 Session Takeaways Key Elements Summary Understand and follow the trends and business deals of your customers Get involved with cross-functional team to understand the financial impact of pricing and contracting decisions Have lunch with your Medicaid folks to discuss the financial impact of the Federal Budget Inflationary Penalty Have lunch with your Government Pricing folks to discuss the financial impact of the ACA Final Rule March 2016 Proprietary Information 26
27 Price Change Optimization Q & A Jennifer Sharpe Sr. Director, Revenue Analytics Collaborative jsharpe@davizta.com Jeffrey Baab Vice President, Life Sciences jbaab@davizta.com March 2016 Proprietary Information
28 davizta Overview Company davizta was founded in 2010 with a fundamental premise: predictable revenue forecasts create healthier companies. By focusing on Revenue Analytics, davizta provides business leaders with enhanced visibility of current and forecasted company performance. This data-enabled vision provides an advantage to companies looking to optimize operations and maximize profits. Solutions Revenue Analytics Software davizta s Revenue Analytics platform, d-rive TM, takes a data-centric approach for fast, accurate, on-demand revenue forecasts. Data Management Revenue SMart is the foundational data solution for all revenue related analysis. Consulting Services Our diverse team of professionals bring unparalleled breadth and depth of experiences in the Life Sciences industry. Leveraging our perspectives in Finance, Operations, Compliance, Contracting, and IT, we pride ourselves on customizing solutions to fit each of our client s unique set of challenges. March 2016 Proprietary Information 28
Drugs, Dollars and Dynamics: The Ups and Downs of Generic Pharmaceutical Pricing. Presented by: Pharmacy Healthcare Solutions, Inc.
Drugs, Dollars and Dynamics: The Ups and Downs of Generic Pharmaceutical Pricing Presented by: Pharmacy Healthcare Solutions, Inc. Learning Objectives 1. Understand factors influencing generic pharmaceutical
More informationSales/Revenue Forecasting and Contract Analytics that Drive Profitability. March 16, 2015 Presented by: Jag Rajan VP of Finance
/Revenue Forecasting and Contract Analytics that Drive Profitability March 16, 2015 Presented by: Jag Rajan VP of Finance 1 TABLE OF CONTENTS Forecasting Drivers 1 Gross to Net Drivers 2 Other Key Drivers
More informationThe Future of Generic Pharmaceuticals
The Future of Generic Pharmaceuticals David R. Gaugh, R.Ph. Senior Vice President, Sciences and Regulatory Affairs Generic Pharmaceutical Association A Look Ahead Aging Demographics 1 YEARS OF AGE A Look
More informationNew Cardinal Health (Post-Spin)
New Cardinal Health (Post-Spin) George Barrett Vice Chairman and Chief Executive Officer Healthcare Supply Chain Services and Chief Executive Officer Cardinal Health, Inc. (post-spin) January 14, 2009
More informationDrafting Pharmacy Benefit Manager Contracts: Controlling Costs, Avoiding Hidden Fees
Presenting a live 60-minute webinar with interactive Q&A Drafting Pharmacy Benefit Manager Contracts: Controlling Costs, Avoiding Hidden Fees Navigating Prescription Drug Pricing Complexities, Selecting
More informationPharmaceutical Compliance Congress: Pricing Update
Pharmaceutical Compliance Congress: Pricing Update November 3, 2011 Jeffrey L. Handwerker Agenda Medicaid Drug Rebate Program OIG Work Plan Draft FULs AMP vs. ASP Comparisons NADAC Survey 340B Program
More informationExaLink services Pricing and contracts
Pricing and contracts Focus on maximizing your revenue, not running your software systems. Client experience that feels like an extension of the team. Adopting managed services is known to be an efficient
More informationCurrent VA Pricing and FSS Issues
Current VA Pricing and FSS Issues CBI Federal Pricing and Contracts for Bio/Pharmaceutical Companies Philadelphia, PA December 9-10, 2014 Marci Anderson, VA OIG Joy Sturm, Hogan Lovells US LLP Why VA and
More informationDerm Drugs: The Price is Too Darn High!
Derm Drugs: The Price is Too Darn High! By Jacob Levitt, MD, FAAD Vice Chairman, Program Director, and Associate Professor The Mount Sinai Medical Center Department of Dermatology New York, NY 1 Disclosures
More informationLuke Johnson, PharmD Clinical Pharmacy Director Pharmastar PBM
Luke Johnson, PharmD Clinical Pharmacy Director Pharmastar PBM Richard Mueller, PharmD, MS-Pharmacoeconomics Pharmacy Director - Community Care Organization Robert Tanner, MBA, MS-Pharmacoeconomics Chief
More informationPut Money Back in Your Classroom Finding the hidden revenue in your pharmacy benefits
Put Money Back in Your Classroom Finding the hidden revenue in your pharmacy benefits Presented by Howard Mazzafro, Vice President Innovative Slide 1 of 25 Solutions. Enduring Principles. Innovative Solutions.
More information{ { { Bona Fide Service Fees and Fair Market Value. Managed Services Operations. Compliance & Risk Advisory Services. Business Intel Products
{ { { Managed Services Operations Compliance & Risk Advisory Services Business Intel Products Bona Fide Service Fees and Fair Market Value June 2015 Results from an Industry Survey CIS-PARTNERS.COM 2 BONA
More informationCoding Systems Understanding NDC and HCPCS
Coding Systems Understanding NDC and HCPCS National Drug Code The National Drug Code (NDC) serves as a universal product identifier for prescription medications approved for human consumption. According
More informationOIG Increases Auditing of Pharmaceutical Manufacturers: Coupons, Part D Remuneration and Medicaid Rebate Administration
For Discussion Purposes Only; Not Intended as Legal Advice. BEIJING BOSTON BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG HOUSTON LONDON LOS ANGELES NEW YORK PALO ALTO SAN FRANCISCO SHANGHAI SINGAPORE
More informationThe U.S. Wholesaler Market: Past, Present and Future
The U.S. Wholesaler Market: Past, Present and Future 2012 H. D. Smith National Sales & Management Conference August 8, 2012 John M. Gray President and CEO HDMA The History of HDMA 1876 2012 Exchange Hall,
More informationWho is Best at Negotiating Pharmaceutical Rebates?
Who is Best at Negotiating Pharmaceutical Rebates? By Lawrence W. Abrams, Ph.D. 12/01/05 Lawrence W. Abrams, Ph.D. Nu-Retail P.O. Box 1285 Watsonville, CA. 95077 831-254-7325 (C.) labrams@nu-retail.com
More informationCindy Kehr Director of Purchasing & Pharmacy Services Keystone Rural Health Center
Cindy Kehr Director of Purchasing & Pharmacy Services Keystone Rural Health Center Statement of Conflicts of Interest Cindy Kehr has no actual or potential conflict of interest in relation to this presentation.
More informationTHE BIOLOGIC DRUG MARKET. ebook: The current state of biologic drugs and the challenges ahead
THE BIOLOGIC DRUG MARKET 2 0 1 7 HOW DO DRUGS AND BIOLOGICS DIFFER? This ebook answers that question, and so much more. OptumRx has summarized the complex and expensive world of biologic drugs for you.
More informationCommercial Pricing and Contracting 101
Commercial Pricing and Contracting 101 Reimbursement and Contracting CBI Conference Philadelphia, PA February 4, 2016 Althea Danzey, Director of Contracting Tina Still, Senior Manager of Contracting Eisai
More informationTAKE A CLOSER LOOK at Biosimilars
Key Stakeholders Frequently Asked Questions Executive Summary Understanding Biosimilars Potential Benefits of Biosimilars TAKE A CLOSER LOOK at Biosimilars 2018 Trends in Biosimilars Report Message From
More informationMedical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs
Medical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs Thursday, March 10, 2016 1:00 2:30 EST 12:00 1:30 CST 11:00 12:30 MST 10:00 11:30 PST Casandra Stockman,
More informationJuly 13, Dear Secretary Price:
July 13, 2017 The Honorable Thomas E. Price, M.D. Secretary U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 Dear Secretary Price: At our meeting on May 16,
More informationWalgreens Rx Supply Chain Transforming to an Outsource Model
Walgreens Rx Supply Chain Transforming to an Outsource Model Michael Bleser Divisional Vice President, Rx Supply Chain & Analytics April 2, 2014 2013 Walgreen Co. All rights reserved. Background BS-Finance
More informationA High-Touch Approach to Improving Patient Access. Using field support to navigate reimbursement challenges
A High-Touch Approach to Improving Patient Access Using field support to navigate reimbursement challenges For the brand and reimbursement teams who must develop commercial strategies for the biopharmaceutical
More informationThe Pharma/Payer Relationship Strategies for the Next Two Years
Health & Life Sciences The Pharma/Payer Relationship Strategies for the Next Two Years by Mark Mozeson Nipon Das, M.D. The power to determine what pharmaceutical products are bought and at what price has
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationYASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.
YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN
More informationCreate Model Forecasts for Data- Based Decision Making. Patrick J. Park, PharmD, MBA Director, Forecasting & Financial Planning Daiichi Sankyo, Inc.
Create Model Forecasts for Data- Based Decision Making Patrick J. Park, PharmD, MBA Director, Forecasting & Financial Planning Daiichi Sankyo, Inc. Disclaimer The views and opinions expressed in this presentation
More informationMaking the right choice: Evaluating outsourced revenue cycle services vendors
White Paper Making the right choice: Evaluating outsourced revenue cycle services vendors Optum www.optum.com Page 1 White Paper Managing resources at today s hospitals and health systems is an ongoing
More informationCapital Market Day June 12, 2012
Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2017 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationOracle Accelerate for Food and Beverage. An Oracle White Paper November 2007
Oracle Accelerate for Food and Beverage An Oracle White Paper November 2007 NOTE: The following is intended to outline our general product direction. It is intended for information purposes only, and may
More informationTransparency Debate in PBM Industry Consumer Driven Healthcare Summit Sept , 2006 in Washington, DC. Marina Tackitt PBMI
Transparency Debate in PBM Industry Consumer Driven Healthcare Summit Sept. 13-15, 2006 in Washington, DC Marina Tackitt PBMI Session Objectives Summarize Complexity of Drug Benefit Management Define Concept
More informationSeeing new opportunity
Seeing new opportunity Cardinal Health Inventory Management Solutions optimize the supply chain at Emory Saint Joseph s Hospital Taking control of the future The Affordable Care Act (ACA) mandates that
More informationThe Executive Guide to Contract and Chargeback Management: How Life Sciences Companies Smartly Automate to Strengthen Profitability
The Executive Guide to Contract and Chargeback Management: How Life Sciences Companies Smartly Automate to Strengthen Profitability 1 Introduction Small and mid-sized life sciences companies are struggling
More informationCloud-Based Solution for Healthcare Supply Chain Management
Cloud-Based Solution for Healthcare Supply Chain Management 1 Healthcare Supply Chain Overview In today s competitive world, cutting the cost of operations is the key to survival in any industry, including
More informationOptum Intelligent EDI. Achieve higher first-pass payment rates and help your organization get paid quickly and accurately.
Optum Intelligent EDI Achieve higher first-pass payment rates and help your organization get paid quickly and accurately. The new benchmark for EDI performance Health care has outgrown commoditized EDI,
More informationArbonne = REsults AUSTRALIA. formulated in switzerland made in the u.s.a.
AUSTRALIA p u r e s w i s s s k i n c a r e formulated in switzerland made in the u.s.a. Arbonne THERE ARE NO GUARANTEES REGARDING INCOME, AND THE SUCCESS OR FAILURE OF EACH INDEPENDENT CONSULTANT, LIKE
More informationCenter for Plain English Accounting AICPA s National A&A Resource Center available exclusively to PCPS members
REPORT February 22, 2017 Center for Plain English Accounting AICPA s National A&A Resource Center available exclusively to PCPS members ASU 2017-01 Clarifying the Definition of a Business On January 5,
More informationUtilize Real World Data to Optimize Patient Savings Programs. Mason Tenaglia Vice President, IMS Institute, Payer and Managed Care Insights
Utilize Real World Data to Optimize Patient Savings Programs Mason Tenaglia Vice President, IMS Institute, Payer and Managed Care Insights September 2018 0 Today we will answer three major questions 1.
More informationTHE BOUNTYJOBS MARKETPLACE FOREWARD
FOREWARD In 2015 we released the first edition of our annual agency recruiting benchmark report, in which we focused on big picture trends in fees and salaries over the past 5 years. As we shifted to the
More informationThe Drug Supply Chain Security Act: An Overview for Health System Pharmacy Staff April 17, 2015
The Drug Supply Chain Security Act: An Overview for Health System Pharmacy Staff April 17, 2015 David Aguero, PharmD Pharmacy Supervisor Inova Alexandria Hospital Alexandria, VA USA Disclosure The opinions
More informationDisclosure. Pre Lecture Questions. Learning Objectives. The Drug Supply Chain Security Act: An Overview for Health System Pharmacy Staff
Disclosure The Drug Supply Chain Security Act: An Overview for Health System Pharmacy Staff The opinions expressed herein are my own, and not necessarily those of my employer or of VSHP April 17, 2015
More informationAmgen Supply Chain Segmentation The Journey to October 23, 2014
Amgen Supply Chain Segmentation The Journey to 2022 October 23, 2014 Introduction Rayne Waller VP Global Supply Chain at Amgen Responsible for: Corporate and Regional Supply Chain Functions Contract Manufacturing
More informationEvaluate the Current Biosimilar Landscape and Strategies to Secure Access. Jim Van Lieshout August 16, 2017
Evaluate the Current Biosimilar Landscape and Strategies to Secure Access Jim Van Lieshout August 16, 2017 1 Disclosure Statement James R. Van Lieshout, Vice President, Trade and Industry Relations Apobiologix,
More informationCardinal Health overview and strategic priorities
Cardinal Health overview and strategic priorities Steve Inacker President, Channel Management Medical Segment Copyright 2011, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. Cardinal
More informationOracle Buys ClearTrial Adds Leading Cloud-based Clinical Trial Operations and Analytics Applications to the Oracle Health Sciences Suite
Oracle Buys ClearTrial Adds Leading Cloud-based Clinical Trial Operations and Analytics Applications to the Oracle Health Sciences Suite April 12, 2012 Oracle is currently reviewing
More informationPrivate Equity: Strategies For 2010 Opportunities in Healthcare Information Technology (HCIT) February 11 th 2010: 10:00 am PST / 1:00 pm EST
Private Equity: Strategies For 2010 Opportunities in Healthcare Information Technology (HCIT) February 11 th 2010: 10:00 am PST / 1:00 pm EST Overview Webinar Protocol Webinar Purpose Opportunities in
More informationTaking Control of Your Fuzzy
Taking Control of Your Fuzzy Front End MassMedic Presentation September 22, 2010 Sanjeev Wadhwani Project Management Consultant Integrated Project Management Company, Inc. Sanjeev Wadhwani Project Manager
More informationTrinity ConTRact: Cornerstone Projects in Contracting Strategy
Trinity ConTRact: Cornerstone Projects in Contracting Strategy With mounting external pressures limiting access and tightening reimbursement, effective contracting is critical to the commercial success
More informationHealthcare s New Change-Maker: The CFO
The role of hospital chief financial officer has changed dramatically over the last 50 years. No longer simply responsible for managing the hospital s finances, today s CFO is a change agent, an indispensable
More informationMDM offers healthcare organizations an agile, affordable solution To deliver high quality patient care and better outcomes
MDM offers healthcare organizations an agile, affordable solution To deliver high quality patient care and better outcomes Many healthcare organizations are struggling with rising costs and inconsistent
More informationBusiness vs. Asset In Practice Potential Impacts of ASU , Clarifying the Definition of a Business
Business vs. Asset In Practice Potential Impacts of ASU 2017-1, Clarifying the Definition of a Business Jeff Ellis (Deloitte) & Tim Kocses (Bristol-Myers Squibb) Current GAAP What is a Business and Why
More informationProven Methods for Accelerating Cost Reduction. Richard Peters, Sr. Director of Surgical Services, Provista
Proven Methods for Accelerating Cost Reduction Richard Peters, Sr. Director of Surgical Services, Provista Presentation objectives Importance of Cost Reduction Sources of Supply Chain Inefficiency Tips
More informationMoberg Pharma AB A DIFFERENT KIND OF PHARMA COMPANY
Moberg Pharma AB A DIFFERENT KIND OF PHARMA COMPANY Corporate Presentation Remium Health Care Capital Market Day Dec 2, 2013 Peter Wolpert, CEO and Founder Disclaimer Statements included herein that are
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationA Seven-Step Approach to a Clinically Integrated Network. April 28, 2016 Track B ACOs, Population Health, Affiliation and Other Issues
A Seven-Step Approach to a Clinically Integrated Network April 28, 2016 Track B ACOs, Population Health, Affiliation and Other Issues Presenters Gayle L. Capozzalo, FACHE Executive Vice President/Chief
More informationFuture Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, September 2015
Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, 28-29 September 2015 (PhD) Agenda Key challenges facing the Pharmaceutical Industry 1. Delivering shareholder/stakeholder
More informationSecond Quarter 2017 Earnings Teleconference. August 1, 2017
Second Quarter 2017 Earnings Teleconference August 1, 2017 Introduction Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements and Non-GAAP Financial Information 3 Our discussions
More informationHospira 2007 Investor Day. APAC Region. Tim Oldham, Ph.D. President, Asia-Pacific. Advancing Wellness. through the right people and the right products
Hospira 2007 Investor Day APAC Region Tim Oldham, Ph.D. President, Asia-Pacific Advancing Wellness through the right people and the right products The APAC Region Asia in Brief: 58% of the world s population
More informationYou should know that the presentation you are about to hear contains forward looking statements.
1 2 You should know that the presentation you are about to hear contains forward looking statements. As you will note on this slide, these statements are made based on management s knowledge and understanding
More informationOptimize Your Incentive Strategy
Optimize Your Incentive Strategy Throughout the Demand Chain Marketers relying on indirect channels undertake unique challenges to capture partner mindshare and maintain sales velocity throughout their
More informationDriving Business Performance
Workforce Scheduling Driving Business Performance How Workforce Scheduling Optimization Aligns the Workforce with Business Demands for Customer Satisfaction and Success While many factors affect an organization
More informationInnovative Routes to Market Rethinking the Life Sciences Distribution Model
Innovative Routes to Market Rethinking the Life Sciences Distribution Model September 2016 Contents Introduction 01 Rethinking the Life Sciences distribution model 02 Conclusions 08 Contacts 09 Introduction
More informationCFO meets M&A: Value creation in the digital age The Dbriefs Driving Enterprise Value series
CFO meets M&A: Value creation in the digital age The Dbriefs Driving Enterprise Value series Lukas Hoebarth, Principal, Deloitte Consulting LLP Nnamdi Lowrie, Principal, Deloitte Consulting LLP Carina
More informationSAP FOR WHOLESALE DISTRIBUTION
SAP FOR WHOLESALE DISTRIBUTION Paul Pretko Senior Principal, Wholesale Distribution Industry 2015 SAP SE or an SAP affiliate company. All rights reserved. 1 WHOLESALE DISTRIBUTION BUSINESS EVOLUTION TRADITIONAL
More informationQuarterly Financial Report of Fresenius Group
Quarterly Financial Report of Fresenius Group applying International Financial Reporting Standards (IFRS) 1 st 3 rd Quarter and 3 rd Quarter 2017 2 TABLE OF CONTENTS 3 Fresenius Group figures at a glance
More informationCardinal Health, Inc. (CAH) - Financial and Strategic SWOT Analysis Review
Cardinal Health, Inc. (CAH) - Financial and Strategic SWOT Analysis Review Cardinal Health, Inc. (CAH) - Financial and Strategic SWOT Analysis Review Sector Publishing Intelligence Limited (SPi) has been
More informationRRecommended. BTI Industry Power Rankings The BTI Consulting Group, Inc. All rights reserved.
EXECUTIVE SUMMARY BTI Industry Power Rankings The Law Firms with the Best Client Relationships in 18 Industries Core Law Firm CClientopia Law Firm RRecommended Law Firm 2017 2017 The BTI Consulting Group,
More informationA Roadmap to Success: Five Guiding Principles to Incentive Compensation Planning. KMK Consulting, Inc.
A Roadmap to Success: Five Guiding Principles to Incentive Compensation Planning KMK Consulting, Inc. Driving informed business decisions with data services and business intelligence solutions There are
More informationGLOSSARY OF TERMS ENTREPRENEURSHIP AND BUSINESS INNOVATION
Accounts Payable - short term debts incurred as the result of day-to-day operations. Accounts Receivable - monies due to your enterprise as the result of day-to-day operations. Accrual Based Accounting
More informationStudent Manual Principles of Economics
Student Manual Principles of Economics Beat The Market On Line: An Interactive Microeconomics Game. GoldSimulations www.goldsimulations.com Beat The Market : Student Manual Published by GoldSimulations
More informationLEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS
LEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based
More informationLeveraging Technology For Strategic Advantage: Why Technology Will Be The Key To Future Competitive Advantage
Leveraging Technology For Strategic Advantage: Why Technology Will Be The Key To Future Competitive Advantage November 8, 2017 I 8:45am -10:15am Monica E. Oss, Chief Executive Officer, OPEN MINDS 1 www.openminds.com
More informationArthur P. Bedrosian, Chief Executive Officer Brian Kearns, Chief Financial Officer. Investor Presentation February 2009
Arthur P. Bedrosian, Chief Executive Officer Brian Kearns, Chief Financial Officer Investor Presentation February 2009 Safe Harbor Statement Except for historical facts, the statements in this presentation,
More informationACCOUNTING FOR MERCHANDISING ACTIVITIES
Chapter 6 ACCOUNTING FOR MERCHANDISING ACTIVITIES Presented by: Endra M. Sagoro Economic Faculty YSU endra_ms@uny.ac.id Operating Cycle of a Merchandising Company Cash Accounts Receivable 2. Sale of merchandise
More information.COM. Pharmaceutical Brand Management Achieving Managed Care Pull-Through Performance
Pharmaceutical Brand Management Achieving Managed Care Pull-Through Performance www.healthcaremedicalpharmaceuticaldirectory.com Healthcare Medical Pharmaceutical Directory.COM Pharmaceutical Brand Management
More informationVALUE-BASED HEALTHCARE A MANUFACTURER S PERSPECTIVE PETER JUHN, MD, MPH VICE PRESIDENT AND GLOBAL HEAD, VALUE-BASED PARTNERSHIPS
VALUE-BASED HEALTHCARE A MANUFACTURER S PERSPECTIVE PETER JUHN, MD, MPH VICE PRESIDENT AND GLOBAL HEAD, VALUE-BASED PARTNERSHIPS NATIONAL CONFERENCE OF STATE LEGISLATURES SAN DIEGO, CA DECEMBER 10, 2017
More informationPHARMACY PROCUREMENT OF DRUG AND NON-DRUG PRODUCTS. Pharmacy Procurement of drug and non-drug products.
Page 1 of 11 SUBJECT: PURPOSE: POLICY: Pharmacy Procurement of drug and non-drug products. To establish the policy and procedures governing the procurement and control of pharmaceuticals and other supplies
More informationData Intelligence and Analytics for Sage 300. An Analytical Framework That Aligns Your Organization For Better Decision Making
Data Intelligence and Analytics for Sage 300 An Analytical Framework That Aligns Your Organization For Better Decision Making Contents 3 Introduction 4 Solution Overview 5 Data Management and Modeling
More informationProfit Management Workshop
Profit Management Workshop How do Franchisees maximize profitability in the face of regulatory changes, a reduced, more expensive labor force and rising cost of goods sold? Profit Management Workshop Developed
More informationSupply Chain Trends and Challenges. Provider & Supplier Perspectives.
Supply Chain Trends and Challenges Provider & Supplier Perspectives gene.schneller@asu.edu 90+ Industry Partners Established in 1986 as a non-profit research center Our Partners: Arizona State University
More informationProvider Network Analytics:
Provider Network Analytics: Achieving Shared Savings in an MSSP ACO by Mapping Network Referral Patterns, Closing Gaps in Service, and Reducing Out of Network Patient Leakage The Client One of Fibroblast
More informationVendor Managed Inventory Solutions for the Grocery Industry
Vendor Managed Inventory Solutions for the Grocery Industry 3160 Pinebrook l Park City, UT 84098 l 435.645.2000 www.parkcitygroup.com Contents Overview... 3 The Issue... 6 The Opportunity... 4 The Solution
More information2016 WHITE PAPER. Healthcare Supply Chain Imperatives
2016 WHITE PAPER Healthcare Supply Chain Imperatives The healthcare industry is rapidly transforming through consolidation from relatively small provider organizations into large provider systems which
More informationNOTABLE INDUSTRY TRENDS TO WATCH
IDN SUMMIT NOTABLE INDUSTRY TRENDS TO WATCH Avalere published their 2016 trends we look GREAT! Political focus on the cost of and access to specialty drugs and biologics will continue Patient engagement
More informationSupplier Oversight PQRI. September Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan
Supplier Oversight September 2014 PQRI Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan Agenda Mylan Background Setting the Stage with a Scenario Current State Thinking Supplier Qualification
More informationGood afternoon, welcome to our annual shareholder meeting. I am Lee Rudow, President and CEO of Transcat and I will provide an overview of the
1 Good afternoon, welcome to our annual shareholder meeting. I am Lee Rudow, President and CEO of Transcat and I will provide an overview of the current state of Transcat an our direction for FY17 and
More informationAn Enterprise Resource Planning Solution for Mill Products Companies
SAP Thought Leadership Paper Mill Products An Enterprise Resource Planning Solution for Mill Products Companies Driving Operational Excellence and Profitable Growth Table of Contents 4 What It Takes to
More informationLannett. Prescribes Automated Business Process Testing 12» 21» 26» 33» 35» 39» 45» insiderprofilesonline.com PAGE 16
How business and IT leaders innovate with SAP solutions Robert Ehlinger, CIO, Lannett Company, Inc. Lannett Prescribes Automated Business Process Testing PAGE 16 12» 21» 26» 33» 35» Going Virtual at GRAY
More informationMcKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals?
McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals? Alexia Cesar, Philip Ma, Navjot Singh, Jeff Smith What's Driving the Recent Surge in New Drug Approvals? In 2012, the
More informationPerformance Benchmarking Toolkit for Health Centers: Tracking Data to Improve Financial Performance
Performance Benchmarking Toolkit for Health Centers: Tracking Data to Improve Financial Performance Health Center Financial Performance Analytics The implementation of healthcare reform produces a heightened
More informationFootwear. SAP Business One. Apparel & Footwear
Footwear SAP Business One Apparel & Footwear Introduction SAP Business One for the Footwear Industry. Integrate and automate critical business processes with Apparel & Footwear for SAP Business One Due
More informationgo vertical. for Microsoft Dynamics AX About MBS Dev Professional Microsoft Dynamics AX Partner Wholesale Distribution Suite
WDS Professional Microsoft Dynamics AX Partner Improve Quality Increase Competitive Edge Enhance Service Deliver Fast Reliable Solutions Wholesale Distribution Suite High Volume Distribution (HVD) Executive
More informationHIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005
HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or
More informationMicrosoft Dynamics ERP. Success for your business. Success for you.
Microsoft Dynamics ERP Success for your business. Success for you. Achieve success on your terms Today s organizations compete in an environment dramatically shaped by current economic conditions as well
More informationFinding Needles in a Haystack Advancing patient care, flow, and access by leveraging clinical data channels
www.pwc.com Finding Needles in a Haystack Advancing patient care, flow, and access by leveraging clinical data channels Agenda Page 1 NSLIJ Health-E Customer Experience 1 2 Payers and Clinical Data 11
More informationBiotech/Patent Licensing
Biotech/Patent Licensing By Jeffrey P. Somers mbbp.com A version of this article appeared in The Journal of Biolaw and Business Vol. 6, No. 3, 2003 CityPoint 230 Third Avenue, 4th Floor Waltham, MA 02451
More informationShifting Pharma Sales Models. Text for a pull out can go heretext for a pull out can go heretext for a pull out can go
Text for a pull out can go heretext for a pull out can go heretext for a pull out can go Text for a pull out can go here Text for a pull out can go here Shifting Pharma Sales Models to Focus on Providing
More informationJeff Bounds, National Account Director. Service-to-Sales Handoff Equity Mining Webinar Playbook to Success
Jeff Bounds, National Account Director Service-to-Sales Handoff Equity Mining Webinar Playbook to Success AGENDA Today We Will Cover Definition of Equity Mining The 4 Phase Approach Service Drive Customer
More information